152 related articles for article (PubMed ID: 29736457)
1. Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial.
Najafian B; Karimi-Sari H; Khosravi MH; Nikjoo N; Amin S; Shohrati M
Contemp Clin Trials Commun; 2016 Aug; 3():55-59. PubMed ID: 29736457
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy of Three Natural Surfactants (Curosurf, Survanta, and Alveofact) in the Treatment of Respiratory Distress Syndrome Among Neonates: A Randomized Controlled Trial.
Mussavi M; Mirnia K; Asadollahi K
Iran J Pediatr; 2016 Oct; 26(5):e5743. PubMed ID: 28203337
[TBL] [Abstract][Full Text] [Related]
3. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
[TBL] [Abstract][Full Text] [Related]
4. Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review.
Magni T; Ragni C; Pelizzi N; Sharma S; Perez-Kempner L; Turkstra E; Nathani J; Orlovic M; Meshchenkova N
Pharmacoecon Open; 2023 May; 7(3):359-371. PubMed ID: 36906631
[TBL] [Abstract][Full Text] [Related]
5. Comparison efficacy of Curosurf and Survanta in preterm infants with respiratory distress syndrome.
Mirzarahimi M; Barak M
Pak J Pharm Sci; 2018 Mar; 31(2):469-472. PubMed ID: 29618436
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Effectiveness of Beraksurf and Curosurf Exogenous Surfactants in the Treatment of Respiratory Distress Syndrome in Preterm Neonates: A Double-blind Randomized Study in the West of Iran.
Eghbalian F; Basiri B; Hatami B; Parsa NM; Jenabi E
Curr Pediatr Rev; 2024 Apr; ():. PubMed ID: 38629362
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.
Speer CP; Gefeller O; Groneck P; Laufkötter E; Roll C; Hanssler L; Harms K; Herting E; Boenisch H; Windeler J
Arch Dis Child Fetal Neonatal Ed; 1995 Jan; 72(1):F8-13. PubMed ID: 7743295
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome.
Bloom BT; Kattwinkel J; Hall RT; Delmore PM; Egan EA; Trout JR; Malloy MH; Brown DR; Holzman IR; Coghill CH; Carlo WA; Pramanik AK; McCaffree MA; Toubas PL; Laudert S; Gratny LL; Weatherstone KB; Seguin JH; Willett LD; Gutcher GR; Mueller DH; Topper WH
Pediatrics; 1997 Jul; 100(1):31-8. PubMed ID: 9200357
[TBL] [Abstract][Full Text] [Related]
9. Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials.
Zhang L; Cao HY; Zhao S; Yuan LJ; Han D; Jiang H; Wu S; Wu HM
Pulm Pharmacol Ther; 2015 Oct; 34():46-54. PubMed ID: 26296793
[TBL] [Abstract][Full Text] [Related]
10. Complications among premature neonates treated with beractant and poractant alfa.
Gharehbaghi MM; Sakha SH; Ghojazadeh M; Firoozi F
Indian J Pediatr; 2010 Jul; 77(7):751-4. PubMed ID: 20589459
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
Pediatrics; 1996 Jan; 97(1):1-6. PubMed ID: 8545199
[TBL] [Abstract][Full Text] [Related]
13. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country.
da Costa DE; Pai MG; Al Khusaiby SM
Pediatr Pulmonol; 1999 May; 27(5):312-7. PubMed ID: 10344709
[TBL] [Abstract][Full Text] [Related]
14. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial.
Egberts J; de Winter JP; Sedin G; de Kleine MJ; Broberger U; van Bel F; Curstedt T; Robertson B
Pediatrics; 1993 Dec; 92(6):768-74. PubMed ID: 8233735
[TBL] [Abstract][Full Text] [Related]
15. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
16. [Protective and curative effects of prophylactic administration of pulmonary surfactant on neonatal respiratory distress syndrome].
Chu GL; Wang J; Xin Y; Zheng J; Zheng RX; Bi DZ
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(13):876-80. PubMed ID: 16759511
[TBL] [Abstract][Full Text] [Related]
17. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants.
Proquitté H; Dushe T; Hammer H; Rüdiger M; Schmalisch G; Wauer RR
Respir Med; 2007 Jan; 101(1):169-76. PubMed ID: 16698258
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity.
Modanlou HD; Beharry K; Padilla G; Norris K; Safvati S; Aranda JV
J Perinatol; 1997; 17(6):455-60. PubMed ID: 9447532
[TBL] [Abstract][Full Text] [Related]
19. Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial.
Jain K; Nangia S; Ballambattu VB; Sundaram V; Sankar MJ; Ramji S; Vishnubhatla S; Thukral A; Gupta YK; Plakkal N; Sundaram M; Jajoo M; Kumar P; Jayaraman K; Jain A; Saili A; Murugesan A; Chawla D; Murki S; Nanavati R; Rao S; Vaidya U; Mehta A; Arora K; Mondkar J; Arya S; Bahl M; Utture A; Manerkar S; Bhat SR; Parikh T; Kumar M; Bajpai A; Sivanandan S; Dhawan PK; Vishwakarma G; Bangera S; Kumar S; Gopalakrishnan S; Jindal A; Natarajan CK; Saini A; Karunanidhi S; Malik M; Narang P; Kaur G; Yadav CP; Deorari A; Paul VK; Agarwal R
J Perinatol; 2019 Sep; 39(Suppl 1):3-12. PubMed ID: 31485014
[TBL] [Abstract][Full Text] [Related]
20. Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration.
Chen CM; Chang CH; Chao CH; Wang MH; Yeh TF
Drug Deliv; 2019 Dec; 26(1):604-611. PubMed ID: 31204848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
